The program aligns with the Trump administration’s broader push to onshore U.S. manufacturing across critical industries. For drugmakers, faster facility approvals could mean shorter timelines between capital investment and revenue recognition.

However, retail investors should not overstate the catalyst. Being selected for a pilot program is a long way from a material earnings driver. Neither company will see immediate revenue or margin lift from the announcement, and the broader pharmaceutical pipeline still depends on clinical trial outcomes and pricing dynamics.

What the news does offer is a reason to look more closely at two stocks sitting at very different points in their respective cycles. Eli Lilly continues to ride the wave of GLP-1 demand and is quietly building an oncology pipeline that could eclipse the weight-loss franchise. Regeneron, by contrast, has been beaten down in 2026 and now trades at levels that may offer a short-term bounce setup.

For investors using the FDA PreCheck news as a starting point, the better short-term trade and the better long-term hold may not be the same name. The charts tell one story, and the fundamentals tell another. Both deserve a fresh look this week.

Eli Lilly’s Oncology Push May Outshine Its GLP-1 Franchise

Eli Lilly has become synonymous with the GLP-1 trade. Mounjaro and Zepbound have transformed the company’s revenue profile and made tirzepatide one of the most valuable drug franchises in the industry. Wall Street is pricing in continued demand growth, and capacity expansion remains a core part of the bull thesis.

However, the more interesting long-term story may be oncology. Lilly has been steadily building a cancer pipeline that targets some of the largest unmet needs in the market, including breast and lung cancer indications. Verzenio is already a multibillion-dollar franchise, and the company’s recent acquisitions and internal programs are aimed at extending that footprint.

The FDA PreCheck inclusion reinforces a pattern of constructive regulatory engagement that benefits Lilly as it scales both franchises. For long-term investors, the GLP-1 story may be the headline, but oncology could be the real durability lever.

Regeneron Offers a Discounted Entry After a Tough 2026

Regeneron has had a difficult 2026. Eylea biosimilar competition has weighed on the company’s most established franchise, and the stock has dropped from highs near $800 in late 2025 to roughly $632 today. That is a meaningful drawdown that has reset expectations and valuation.

However, Regeneron is not a one-product story. Dupixent, partnered with Sanofi, continues to expand into new indications and remains a major growth contributor. The company also has a deeper oncology and immunology pipeline, including Libtayo and several early-stage programs that could surface meaningful catalysts over the next 12 to 18 months.

The FDA PreCheck designation does not change the Eylea biosimilar dynamic, but it does signal that Regeneron’s manufacturing footprint is viewed favorably by regulators. For investors looking at a stock that has been left for dead, the combination of compressed valuation and a steady pipeline makes Regeneron worth a second look.

Technical Setup Favors REGN for a Near-Term Bounce

Regeneron’s chart shows the early signs of a reversal attempt. Shares trade at $631.81, still below the 50-day simple moving average at $664.44, which remains the first resistance level to clear. However, the MACD line has crossed above its signal line, and the histogram has flipped positive at 6.02. Both MACD lines are still in negative territory, suggesting the trend change is early, but the momentum is improving. Volume has remained steady through the basing process. A break above the 50-day SMA could open the door to a move back toward the $700 area, offering a clean short-term setup.

Eli Lilly looks technically stronger but offers less immediate upside. Shares closed at $1,229.93, up 1.81% on the day, and are well above the 200-day SMA at $978.29. The MACD line at 34.85 sits above the signal line at 30.97, with the histogram positive at 3.88. That confirms an ongoing uptrend, but the price is extended versus the moving average. New entrants may prefer to wait for a pullback toward the $1,100 area before adding. For existing holders, the chart supports continued accumulation rather than chasing here.

Why Biotech May Be the Next Hot Sector

Biotech has lagged the broader market for much of the past two years. Higher interest rates, drug pricing reform, and uncertainty around the regulatory environment kept capital on the sidelines. However, the setup is changing.

The FDA PreCheck program signals a more constructive regulatory tone, particularly around domestic manufacturing. Onshoring incentives, an aging U.S. population, and a wave of late-stage oncology and obesity catalysts could reset sentiment. If rate cuts continue and small-cap biotech stocks catch a bid, large-cap names like Lilly and Regeneron may benefit from a sector-wide rotation as investors look for both growth and defensive characteristics.

Two Ways to Play Pharma’s Onshoring Tailwind

The FDA PreCheck announcement is not a transformative catalyst for Eli Lilly or Regeneron, but it does point investors toward two distinct opportunities. Regeneron offers a near-term technical setup for a bounce after a steep 2026 decline, supported by a positive MACD crossover and a clear resistance level to break.

Eli Lilly remains the long-term compounder, with an oncology pipeline that may ultimately rival its GLP-1 franchise. Investors do not need to choose one over the other; the timeframes differ, and that should drive the allocation decision.

But framing them that way misses the bigger picture.

In today’s market, passive money flows pour into index funds regardless of valuation. Algorithmic trading and momentum strategies reward quality businesses with durable earnings power. And in an environment defined by uncertainty — tariff disruptions, rate volatility, geopolitical noise — investors are increasingly willing to pay a premium for companies that don’t need a perfect macro backdrop to execute.

High P/E stocks that are still worth buying share a common thread: their earnings growth is outrunning their valuation. When the underlying business compounds at a fast enough rate, a premium multiple doesn’t stay premium for long. That’s the case for Walmart, Eli Lilly, and Caterpillar. Each comes from a different sector. Each carries a valuation that will scare off value investors. And each has a credible path to growing into — and beyond — that multiple over the next several years.

In a market where many investors are focused on speculative bets, these are best-in-class businesses in sectors where being the best matters enormously. Here’s why it’s worth paying the premium for these high P/E stocks.

Walmart Is No Longer Just a Retailer — And the Market Knows It

The knock on Walmart stock has always been the same: you’re paying a consumer staples P/E for a grocery store. And today, you could say you’re paying a tech stock premium. But that framing is increasingly obsolete.

Walmart has actively invested in AI-driven retail. The retailer embedded its own chatbot, Sparky, into platforms such as ChatGPT and Google Gemini. The company is executing a two-front competitive strategy: holding its own against Costco (NASDAQ: COST) in the brick-and-mortar warehouse club format through Sam’s Club, while simultaneously closing the gap on Amazon (NASDAQ: AMZN) in e-commerce. Global e-commerce sales have surged, and Walmart’s U.S. e-commerce growth has been a consistent double-digit story, with the company also exploring drone delivery to stay competitive with Amazon.

Meanwhile, the customer mix is shifting in Walmart’s favor. Walmart’s latest earnings revealed growth from higher-income customers and a rise in e-commerce, with higher-income households increasingly prioritizing value as they look to stretch their dollars. That’s a market share story. Affluent consumers discovering Walmart’s improved shopping experience don’t tend to leave once they arrive.

Walmart’s chief financial officer (CFO) indicated that the company will likely see average operating income growth of about 10% each year. At a 42x P/E, that’s a growth rate that can work — especially for a company that increasingly looks less like a retailer and more like a technology-enabled consumer ecosystem.

Eli Lilly’s GLP-1 Lead Is the Story — But It’s Not the Whole Story

Eli Lilly built its premium valuation on the back of tirzepatide — the active ingredient behind Mounjaro and Zepbound, its blockbuster diabetes and obesity franchise. That catalyst isn’t slowing down. Mounjaro generated $8.7 billion in Q1 2026 alone, overtaking Merck’s Keytruda as a top revenue driver, and Lilly raised its full-year 2026 sales forecast to as high as $85 billion on surging demand for its obesity drugs.

But investors focused only on GLP-1 are missing the depth of Lilly’s pipeline. The company recently received approval for orforglipron — the first oral GLP-1 receptor agonist small molecule for obesity — and launched donanemab for early symptomatic Alzheimer’s disease, while simultaneously advancing a diversified oncology portfolio spanning CDK4/6 inhibition, BTK inhibition, and bispecific T-cell engagers.

Lilly is using its GLP-1 financial strength to fund an aggressive dealmaking strategy, with head of corporate development Jacob Van Naarden noting that the company is now “wider than early-stage bets.” Recent acquisitions and agreements include Verve Therapeutics for gene therapies for heart disease, Scorpion Therapeutics for oncology, and Adverum Biotechnologies for a gene therapy targeting wet age-related macular degeneration. CNBCNasdaq

LLY’s current P/E of 40x is actually 23% below its 10-year historical average — making this one of the rare cases where a stock that looks expensive by market standards is actually trading at a discount to its own history. The obesity market alone is a multi-decade tailwind. The rest of Lilly’s portfolio is the upside.

Caterpillar Is an Industrial — With an AI Infrastructure Angle

Caterpillar has always been a bellwether for the global economy. But something has changed. The market is now treating it as a dual-identity stock: part heavy industrial, part AI infrastructure play. Both narratives are intact.

After a record 2025 with $67.6 billion in full-year sales and revenues, Caterpillar entered 2026 with a $51 billion dealer backlog and Wall Street expecting roughly 15% year-over-year revenue growth in Q1 2026. Construction Industries’ total sales in Q1 2026 came in at $7.16 billion, up 38% year over year, driven by higher sales volume and favorable price realization.

The AI angle comes through Caterpillar’s Power & Transportation segment. Caterpillar’s power generation business has become a major driver as data center developers look for fast, reliable electricity, especially for large AI campuses — a key reason the stock has rallied sharply in 2026.

Favorable trends in construction activity, commodity demand, data center investments, and energy-transition projects continue to support Caterpillar’s growth opportunities, while the company’s expanding aftermarket services business, known for its high margins, further strengthens its earnings profile. CAT shares have gained over 137% in the past year, outpacing both its industry peers and the broader S&P 500.

For a company building the physical infrastructure that enables the digital economy, paying a premium multiple doesn’t seem like a stretch.

High P/E Stocks with Long-Term Payoffs

Paying 40x earnings for any stock requires conviction. Paying that premium for three of them requires a thesis. The thesis here is straightforward: in a market where passive flows reward the biggest and best companies regardless of daily valuation readings, quality wins over time.

Walmart, Eli Lilly, and Caterpillar don’t share a sector or a growth story. What they share is dominance — in retail and technology convergence, in pharmaceutical innovation, and in the physical infrastructure buildout that underpins both the old economy and the new one. Each has multiple ways to win from here. Each has an earnings growth trajectory that can justify its current multiple.

High P/E stocks get punished hardest when earnings disappoint. That’s the risk. But when the underlying businesses are executing at this level, the risk of overpaying looks less threatening than the risk of waiting for a cheaper entry that may never come.

While many investors focus on well-known blue-chip names, some overlooked dividend stocks and dividend-focused ETFs may offer even stronger upside opportunities. Companies like Lowe’s (NYSE: LOW), American States Water (NYSE: AWR), and the Vanguard Dividend Appreciation ETF (NYSEARCA: VIG) combine consistent dividend growth with solid business fundamentals, making them attractive options for income-focused investors in 2026.

Plus, it never hurts to hold dividend stocks – especially when markets get uncontrollably volatile. Not only can they help protect your portfolio, but they can also help generate healthy passive income along the way.

That being said, here are three dividend stocks you may want to consider.

Lowe’s Continues Rewarding Shareholders Despite Market Pressure 

Down, but not out, Lowe’s just raised its quarterly cash dividend to $1.25, which is payable on August 5 to shareholders of record as of July 22. That’s a 4% increase from its prior dividend payout of $1.20. 

“The momentum we are building across our strategic initiatives continues to position Lowe’s for long-term growth,” said Marvin R. Ellison, Lowe’s chairman, president and CEO, as quoted in a company press release. “Today’s dividend increase underscores the board’s confidence in the company’s trajectory, our disciplined capital allocation strategy and our commitment to delivering sustainable shareholder value.”

In addition, the company just delivered a strong Q1 2026 earnings report. The home improvement giant reported EPS of $3.03, which beat by six cents. Revenue of $23.1 billion, up 10.4% year over year, beat by $220 million. Comparable sales also climbed 0.6%, showing that demand for home improvement projects remains resilient despite ongoing pressure from high interest rates and cautious consumer spending.

American States Water Remains a Reliable Dividend King

With a yield of 2.64%, Dividend King American States Water provides water and electric services with a strong history of consistent dividend increases. In fact, it’s paid out a dividend every year since 1931. Its most recent dividend of $0.5040 will be paid out on June 2 to shareholders of record as of May 18. This is now its 360th consecutive dividend payment.

The company has grown its quarterly dividend rate at a compound annual growth rate (CAGR) of 8.5% over the last five years since the second quarter of 2021, and has achieved a 10-year CAGR of 8.3% in its calendar year dividend payments through 2025. The company’s current policy is to achieve a compound annual growth rate in the dividend of more than 7% over the long-term, as noted in its Q1 2026 earnings press release.

Why VIG Remains a Top Dividend ETF for Long-Term Investors

We can also look at ETFs such as the Vanguard Dividend Appreciation ETF, which just paid a dividend of just over 83 cents a share on March 31. Before that, it paid out just over 88 cents per share on December 24, 2025.

With an expense ratio of 0.04% and a monthly yield of 1.56%, the VIG is also an attractive opportunity that tracks the performance of the S&P U.S. Dividend Growers Index and invests in large-cap stocks with a record of dividend growth. Some of the VIG ETF’s 338 holdings include Apple (NASDAQ: AAPL), Microsoft (NASDAQ: MSFT), Broadcom (NASDAQ: AVGO), JPMorgan (NYSE: JPM), Eli Lilly (NYSE: LLY), Visa (NYSE: V), Exxon Mobil (NYSE: XOM), UnitedHealth Group (NYSE: UNH), Mastercard (NYSE: MA) and Costco Wholesale (NASDAQ: COST).

Final Thoughts on Overlooked Dividend Stocks

In uncertain markets, overlooked dividend stocks like these can offer a valuable combination of income, consistency, and upside potential — making them worth a closer look for investors focused on building wealth over time. Lowe’s continues to benefit from resilient home improvement demand, American States Water offers one of the strongest dividend track records on the market, and the Vanguard Dividend Appreciation ETF provides diversified exposure to companies with a history of rewarding shareholders.

With high-yield funds, you aren’t constantly timing withdrawals or watching market swings. Instead, these funds are a passive investment idea that can deliver consistent income while still offering long-term growth potential.

Some of the best options for finding stocks with high yields are exchange-traded funds (ETFs). ETFs offer diversification, professional management, and low costs. These are three traits that become increasingly important as you move from accumulation to preservation and income. If this sounds like the kind of investment that may fit your portfolio, here are three dividend income ETFs you may want to consider.

Global Dividend Income ETF for International Diversification

If you want to diversify beyond U.S. markets, the Vanguard International High Dividend Yield Fund ETF (NYSEARCA: VYMI) provides access to high-quality global income stocks. It also yields 3.64%.

With an expense ratio of 0.17%, the ETF targets 1,534 global companies, such as Nestle, Novartis, Toyota, and Shell. All are established companies with strong balance sheets, global revenue streams, and a history of returning capital to shareholders.

Most recently, the fund paid out a dividend of just over 79 cents a share on March 24. Before that, it paid 93 cents per share on December 23. It paid just over 70 cents per share on September 23. And before that, it paid a dividend of just over $1.07 per share on June 24. While international dividends can be volatile, with currencies, VYMI has delivered meaningful income over time.

Beyond yield, VYMI provides an important portfolio benefit: geographic diversification. Retirees who rely heavily on U.S. stocks may be overexposed to domestic issues. By incorporating international dividend stocks, you can diversify your risk.

Low-Cost Dividend Growth ETF for Long-Term Stability

 With an expense ratio of 0.04% and a quarterly dividend, the Vanguard Dividend Appreciation ETF (NYSEARCA: VIG) tracks the performance of the S&P U.S. Dividend Growers Index.

In addition, the VIG ETF has a well-diversified portfolio of 334 stocks and offers a low-cost, resilient, growth-oriented option for smart investors. 

Some of its other holdings include Broadcom (NASDAQ: AVGO), Microsoft (NASDAQ: MSFT), JPMorgan Chase (NYSE: JPM), Apple (NASDAQ: AAPL), Visa (NYSE: V), Eli Lilly (NYSE: LLY), and Exxon Mobil (NYSE: XOM). Making the VIG ETF even more attractive, it yields about 1.66% and just paid out a dividend of just over 83 cents per share on March 31. Before that:

• It paid out a dividend of just over 88 cents per share on December 24.
• It paid out a dividend of just over 86 cents per share on October 1.
• It paid out a dividend of just over 87 cents per share on July 2.

High-Yield Covered Call ETF for Enhanced Monthly Income

With a monthly yield of 1.61% and an expense ratio of 0.56%, the Amplify CWP Enhanced Dividend Income ETF (NYSEARCA: DIVO) holds large-cap companies that have a strong history of dividend growth. It also uses a covered call strategy on individual stocks to offer high total returns.

“DIVO seeks investment results that correspond generally to an existing strategy called the Enhanced Dividend Income Portfolio (EDIP),” as noted by AmplifyETFs.com. That strategy attempts to generate income through dividends and short-term covered calls in an effort to increase cash flow and consistent annual income. In addition, with that strategy, the EDIP holds blue-chip stocks from the S&P 500, the Dow 30 and the S&P 100.

It paid a dividend of just over 18 cents per share on April 30.

Why Dividend Income ETFs Belong in a Long-Term Portfolio

At the end of the day, building reliable passive income doesn’t have to involve chasing individual dividend stocks or constantly monitoring market volatility. Dividend income ETFs like VYMI, VIG, and DIVO offer a practical, diversified approach to generating cash flow while reducing single-stock risk. Each fund serves a different purpose—VYMI provides international diversification, VIG focuses on long-term dividend growth, and DIVO offers enhanced income through covered call strategies.

That flexibility allows investors to tailor their exposure based on their stage of life, risk tolerance, and income needs. For retirees, these ETFs can help supplement income streams without requiring active portfolio management. For younger investors, reinvesting those distributions can create powerful compounding over time. In either case, the right mix of dividend income ETFs can help create a portfolio designed to produce income today and financial stability tomorrow.

With the market straining for decisively optimistic data, the news that second-week scripts for Foundayo generated only modest results led to a recent sharp decline in LLY stock. Fundamentally, the core distraction is that Wegovy — manufactured by Novo Nordisk (NYSE: NVO) — saw far more prescriptions in its second week than Eli Lilly’s new oral therapeutic.

That’s problematic from a patient experience standpoint because of a rising debate in efficacy between the two weight-loss drugs. According to a report cited by BioSpace, Wegovy (under the 25mg dosage) showed 3.2% greater weight loss than Foundayo. Thus, the implication is that, despite the arrival of the new competitor, patients will likely prefer the former drug.

However, the nuance here centers on logistics, of which Wegovy is a nightmare. Patients must take it on an empty stomach with exactly four ounces of water and wait 30 minutes before eating. On the other hand, Foundayo can be taken any time of day, with or without food. Eli Lilly believes this attribute offers a real-world advantage that will lead to superior long-term adherence.

From this angle, it’s quite possible that LLY stock could be undervalued — or is at least overly penalized by the “fear discount.” According to medical literature, when a therapeutic’s regimen becomes increasingly complicated, adherence becomes problematic. What the bulls are arguing for Eli Lilly, then, is that while Novo Nordisk may offer the slightly more effective drug, Eli Lilly brings to the table superior accessibility.

Another component that adds fuel to the fire is the upcoming Q1 earnings report, scheduled for April 30 (before the opening bell). If management can reveal data that supports its assertion that the long-term trajectory of Foundayo is more encouraging than recent reports have suggested, that could provide a strong catalyst for LLY stock.

An Inductive Approach to Analyzing LLY Stock

While the nuances behind Foundayo provide an intriguing narrative, it’s also difficult to fully understand how much of this dynamic has been reflected in Eli Lilly stock — if at all. There’s an assumption that if the pharma giant beats its headline numbers (earnings per share of $6.97 on revenue of $17.83 billion), LLY could be off to the races. However, that proposition likely depends on how much of the news has been baked into the share price.

Frankly, that methodology gets into a subjective game that’s difficult to assess quantitatively. That’s why I prefer a discretized inductive analysis to condition forward probabilities based on objective data.

Now, induction is really just a fancy term for pattern recognition. This philosophy relies heavily on the uniformity of nature, that whatever happened in the past is likely to repeat in the future. It’s another way of assigning correlations: should X happen, Y is likely to happen. Certain disciplines within technical analysis operate the same way. For example, if you see a head-and-shoulders pattern, that apparently signals a higher likelihood of a descending share price.

Unfortunately, the inputs of technical analysis are often extremely subjective, which is why I believe discretization is critical. By looking at discrete signals (such as the frequency of positive and negative weekly candlesticks), the data inputs of the underlying methodology are objective and consistent.

Personally, I run Markov simulations on potentially viable securities like LLY stock, which weigh forward probabilities based on the current behavioral state of the system. I define a state as a discretized 10-week period of price action. From there, I inductively calculate the probability of the next behavioral state materializing based on the current state.

In other words, I attempt to answer this question: given the last 10 weeks of price action, what is the likely forward distribution of the next 10 weeks? It’s the search for this answer where things get interesting for speculators.

Comparing Expectations Versus the Baseline for Eli Lilly Stock

On any given 10-week period, a trader holding LLY stock is likely to enjoy a noticeably strong upward bias. Out of 362 rolling 10-week sequences going back to January 2019, 233 of them popped higher than the starting price. This gives us an exceedance ratio of 64.4%. Further, the distribution of average outcomes would typically land LLY between $870 and $950, with probability density peaking at around $905.

However, we’re not interested in analyzing LLY stock as an aggregate of all possible 10-week sequences. Instead, we’re focused on the current signal. In the past 10 weeks, LLY printed only three up weeks, leading to an overall downward slope. Under this 3-7-D signal, the exceedance ratio jumps to 80%. Further, the forward distribution lands between $780 and $1,130.

Before you jump on the bullish bandwagon for Eli Lilly stock, a serious word of caution: we’re talking about a very small sample size of the aforementioned signal. Also, the forward distribution — based on a mixture of Bayesian-lite inference and conditioned historical data — does show expanded risk exposure (along with the enhanced reward profile).

Basically, LLY stock has become a high-risk, high-reward play — but the data (though diminutive in sample size) leans bullishly.

If you’re a diehard contrarian but rationally approach your trade through a quantitative lens, the idea to look into may be the 990/1000 bull call spread expiring June 18. This narrow spread requires LLY stock to rise through the $1,000 strike at expiration to be fully profitable. If it does, the maximum payout clocks in at 150%.

From a week-to-week Markov simulation, LLY historically has a tendency to rise in the latter weeks under 3-7-D conditions, making the $1,000 target potentially feasible. But it’s also fair to point out that a lot is riding on Eli Lilly’s earnings and how it frames Foundayo prescriptions. Ultimately, it’s a trade to consider if you don’t mind throwing caution to the wind.

But what’s considered a high P/E ratio? That’s a relative term. A standard measure is to look at the average P/E ratio of all the stocks in the S&P 500, which as of the market close on March 6, 2026, was 27.4x.  

For investors of a certain age, having an average P/E around 27 would seem absurd. Just 30 years ago, a P/E above 10 was considered high-risk. And that’s why many stocks are deemed expensive.  

That said, many of these high P/E stocks have continued to defy gravity. And that’s due to something that every investor needs to focus on, which is growth. Many of these companies, such as NVIDIA Corp. (NASDAQ: NVDA) have been growing at exceptional rates that make investors eager to bid up their respective stocks.  

You also need to consider that many stocks are expensive to the S&P 500 but may not be expensive compared to their market sector. For example, technology companies, in general, will have higher P/E ratios compared to utility companies because they provide outsized growth.  

This creates a clash of philosophies for investors. On the one hand, stocks don’t move in the same direction forever. Many stocks are down sharply in 2026 due to profit-taking and sector rotation. At the same time, time in the market is more important than timing the market. Investors take a risk by moving out of a high P/E stock that still has upside potential.  

Here are three high P/E stocks that fit that criteria. They’re expensive but have a long runway to grow into their valuations.  

High P/E Stock to Buy: Palantir Technologies 

Palantir Technologies (NASDAQ: PLTR) is as polarizing as it is expensive. Many investors won’t touch the stock because of its contracts with the federal government, and specifically the U.S. Department of War. Other investors will point to PLTR’s high P/E of around 241x as of this writing.  

Let’s put that into perspective. In the introduction, I said that technology stocks frequently have sector averages higher than the S&P 500. Palantir is in the software sector, where the average P/E is around 41x. That still makes Palantir very expensive.  

However, both of these arguments fail to capture the reasons to own PLTR stock. To begin with, as of the company’s most recent earnings report, Palantir generates about 44% of its revenue from commercial customers. This covers sectors ranging from healthcare to consumer staples to energy.  

Second, traditional P/E ratios can be a misleading valuation metric for software companies with high reinvestment rates. This is because GAAP earnings are reduced by heavy spending on R&D and sales. These are investments that drive future growth rather than represent true economic losses. Therefore, P/E can make a profitable, compounding business look expensive on paper. 

For Palantir specifically, stock-based compensation further distorts GAAP earnings, making the P/E ratio an especially poor standalone metric. Investors may find it more useful to focus on free cash flow, which strips out some of these distortions and better reflects the business’s cash-generating power. On that basis, Palantir has shown accelerating FCF growth alongside a debt-free balance sheet, which suggests underlying business health even when headline earnings metrics appear stretched. 

High P/E Stock to Buy: Eli Lilly 

Another way to determine if a high P/E stock is worth chasing is the company’s position within its sector. That’s a solid rationale for owning Eli Lilly & Co. (NYSE: LLY). LLY stock is up about 14% in the 12 months ending March 6. However, the stock’s momentum has stalled in 2026. Valuation isn’t the only reason, but it’s one of them.  

That said, Eli Lilly is the undisputed leader in the GLP-1 weight loss category. That’s a sector that’s expected to have many years and multiple billions of dollars of growth potential. There’s room for more than one company in this space. But Lilly has an entrenched position that will be difficult to replace.  

Plus, Lilly isn’t just about GLP-1 drugs. The company has a long history of expertise in Alzheimer’s disease, oncology, cardiovascular disease, and immunology. It’s also one of the companies that is aggressively pursuing treatments for Alzheimer’s disease. That’s reflected in the company’s expansive pipeline that includes 36 candidates in Phase 3 trials.  

High P/E Stock to Buy: Walmart 

Walmart (NASDAQ: WMT) is another high P/E stock for investors to consider. For one thing, the company recently switched its listing from the New York Stock Exchange (NYSE) to the NASDAQ to better reflect its ongoing investment in technology in areas like robotics and artificial intelligence (AI).  

The retailer is an example of a company that’s not resting on its laurels. Rather than conceding an inch of ground to Amazon (NASDAQ: AMZN), Walmart has aggressively taken the fight to them with its Walmart+ program that has been integral to the company’s post-2020 growth.  

Plus, Walmart split its stock in January 2025 to make it more accessible for its employees and other retail investors. Year-over-year (YOY) growth has started to accelerate in the last two quarters of its 2026 fiscal year, which reinforces management’s commentary that the company is capturing a higher share of wallet from higher-income consumers who are shopping at Walmart for discretionary items even as lower-income consumers stick to staples.  

All of this reinforces the company’s rock-solid balance sheet that allows it to buy back shares and continue to increase its dividend. In fact, Walmart is a Dividend King, having increased its dividend in each of the last 53 consecutive years.  

When You Buy the Best, the Rules Can Be Flexible 

High P/E stocks are not for every investor, and the valuation risk is real. But Palantir, Eli Lilly, and Walmart each represent companies with durable competitive advantages and credible paths to growing into their current valuations.  

Palantir’s FCF growth and AI-driven expansion, Lilly’s dominance in GLP-1 and a deep clinical pipeline, and Walmart’s relentless operational reinvention make these more than just expensive tickers. For investors with a long time horizon and the conviction to hold through volatility, these stocks offer something increasingly rare in today’s market: genuine upside with a fundamental story to back it up. 

At the culmination of the consolidatory action, however, a breakout move could materialize. Now, I’m not a big fan of technical analysis as I now find the discipline to be largely built on unfalsifiable heuristics. That said, the potential breakout could come in the form of a major catalyst: positive results stemming from this Wednesday’s fourth-quarter earnings report.

On paper, Wall Street analysts will be looking for earnings per share to hit $6.96 on revenue of $17.9 billion. In the year-ago quarter, the healthcare juggernaut posted EPS of $5.32 on revenue of $13.53 billion, beating the consensus targets of $5.08 and $13.43 billion. Generally speaking, Eli Lilly tends to exceed expectations, so observers will likely have some confidence in the company.

For proper context, LLY stock has enjoyed a robust performance, and it’s not purely based on technical speculation. In the past five years, LLY has moved up 414% and that’s largely off the back of an impressive expansion of the top line. For example, in Q4 of 2022, sales grew only 7.53% year-over-year. If Eli Lilly hits its mark this time around, growth would reach over 32% YOY.

Still, the main concern among smart money traders is that most of the optimism is already baked in. Technically, LLY stock has gained 28% in the trailing 52 weeks, which is a very solid performance. It’s not clear, then, that the upside hasn’t been baked in. Nevertheless, I’m fascinated by the bull flag amid other compelling contexts.

Volatility Skew Reveals Potentially Discounted LLY Stock Call Options

Before diving into higher-level analyses, it’s important to exhaust all available first-order insights. One of the most informative is volatility skew, which identifies implied volatility (IV) for the strike price spectrum of a given expiration date.

In the case of the Feb. 20 options chain, the volatility skew for LLY stock primarily shows a controlled smile of both the put-side IV and the call-side IV, with the puts dominating the overall proceedings. Effectively, this framework implies that the main priority among smart money traders is downside protection and insurance.

On the upper price boundaries, put IV is conspicuously above calls, which mechanically functions as a short position against LLY stock. Now, I don’t believe that these institutional investors are net short Eli Lilly per se. Rather, the motivation is likely to protect their long-side exposure against downward volatility. I believe this structure is significant because it suggests that the smart money still wants to participate in LLY; it just wants to do so hedged.

On the other end of the spectrum, put IV is also elevated at the lower boundaries. This setup possibly indicates the purchase of tail risk. Essentially, it’s possible that Eli Lilly stock could tumble from its bull flag formation. If the technical setup fails, then the anticipated breakout move could easily go the wrong direction. Again, I think it’s telling that the smart money, instead of selling LLY outright, is buying insurance instead.

To be sure, volatility skew can only show so much. While we understand the hedging motivations of sophisticated market participants, we don’t have any idea of where LLY stock may end up. That’s because the distortions that we see in the skew do not necessarily represent the strike prices where demand is concentrated. Instead, the curvature stems from a surface-level distortion arising from holistic trading activity.

For further insight into the actual kinetic parameters of LLY stock, we must consider another analysis.

Laying Out the Battlefield for Eli Lilly Stock

While we may understand certain sentiment nuances of the smart money, we need a way to translate this data into actual insights. For the initial step, we can turn to the Black-Scholes-derived expected move calculator. This model projects Eli Lilly stock to land between $952.22 and $1,120.84 for the Feb. 20 options chain.

Where did this dispersion come from? Black-Scholes assumes a world where stock market returns are lognormally distributed. Under this framework, the above dispersion represents how LLY stock would symmetrically fall one standard deviation from the spot price (while accounting for volatility and days to expiration).

What it boils down to is that Black-Scholes assumes that in 68% of cases, LLY will trade between roughly $952 and $1,121 when Feb. 20 rolls around. Although a very reasonable assumption, it’s not the most helpful dispersion because of its width. As debit-side traders, we would be required to cover the entire gap of the spectrum, which comes out to almost 18% ($1,120.84 divided by $952.22).

Fundamentally, the obstacle is that Black-Scholes calculates its projections independent of structure. That’s why no matter what context the model is used in, it always spits out a perfectly symmetrical envelope. However, forward probabilities are asymmetrical precisely because in the market, prior structure has an influence on forward pathways.

In order to narrow our projections, we need to condition forward probabilities based on the current market context. For that, we can turn to the Markov property.

Drilling into Second-Order Analyses

Under Markov, the future state of a system depends solely on the current state. That’s a fancy way of saying that forward probabilities should not be independently calculated but rather assessed under ecosystem context. To use a simple football analogy, a 20-yard field goal is an easy chip shot. Add snow, wind and playoff pressure, and these odds may change dramatically.

Again, the main difference between the Black-Scholes model and the Markov property is dependency. With the former, volatility is an independent input and context isn’t even integrated into the framework. With the latter, forward probabilities hinge on the current structure of the asset.

For LLY stock, in the last 10 weeks, the security printed six up weeks. However, the overall slope of this trend was downward. Using a combination of enumerative induction and Bayesian-lite inference, we can see that under 6-4-D conditions, LLY’s forward probability radically changes from normal expectations. Over the next 10 weeks, we would anticipate the stock landing between $1,000 and $1,200, with probability density being prominent at $1,125.

Over the next five weeks, LLY stock is likely to range between $1,025 and $1,150, with the probability density peaking between $1,090 and $1,117. What’s interesting here is that my probabilistic range doesn’t actually conflict with the dispersion that Black-Scholes provided. Instead, it narrowed the likely landing zone to a much tighter range.

With this information, I’m liking the 1,110/1,120 bull call spread expiring Feb. 20. The net debit required is relatively cheap compared to the other spreads at $460. Should LLY stock rise through the $1,120 strike at expiration (which is not an unrealistic target), the maximum profit would be $540, a payout of over 117%. Breakeven comes in at $1,114.60, adding to the trade’s probabilistic credibility.

This year’s resolution stocks aren’t short-term trades; they’re durable compounders designed to outperform through full market cycles. Each name outlined below combines solid balance sheets, expanding cash flows, and exposure to sectors driving capital rotation as interest rates stabilize. For 2026, focusing on leaders with enduring competitive advantages could turn this year’s investing resolutions into lasting portfolio gains. 

Microsoft: The AI Powerhouse Among the Best Stocks for 2026 

Microsoft Corp. (NASDAQ: MSFT) remains a cornerstone of the “best stocks for 2026” theme thanks to its central role in artificial intelligence adoption. Its Azure cloud infrastructure underpins the global AI ecosystem, while its Copilot integrations across Office, Dynamics, and Windows embed generative technology into everyday workflows. With mid-teens EPS growth and recurring revenue tailwinds, the company offers a balanced blend of innovation and defensive profitability. 

MSFT stock was up more than 15% in 2025, but that was slightly below the S&P 500 and well below the NASDAQ. However, investors betting on the multiyear AI buildout can use Microsoft as a stable anchor. The company’s 3% free cash flow yield and steady dividend hikes create a cushion for volatility.  

A potential trade: accumulate shares on dips below $400, with a 12–18 month target of $475, aligning with accelerating AI monetization and enterprise IT spending. A covered call strategy can also enhance yield while retaining upside participation. 

Eli Lilly: Healthcare Growth That Defies Gravity 

Eli Lilly & Co. (NYSE: LLY) stands out as one of the best healthcare stocks for 2026, driven by continued demand for its market-leading GLP-1 therapies in obesity and diabetes. These category-defining drugs are transforming health outcomes and reshaping the global pharmaceutical landscape. As manufacturing capacity expands, revenue growth and operating margins should remain robust through the mid-decade. 

LLY stock jumped over 39% in 2025, easily outpacing the broader market and making the stock a shining star in a weak biopharmaceutical industry. While valuation is elevated, it reflects Lilly’s unmatched revenue visibility and strong R&D pipeline. Long-term investors seeking resilience beyond cyclical sectors can rely on LLY’s durable growth and defensive profile. The company pays a dividend with a payout of $6 per share on an annual basis.  

A potential trade: accumulate shares near $700, targeting $850 by year-end 2026 as production scales and payer coverage broadens. Pairing LLY with a diversified healthcare ETF can help balance risk while anchoring exposure to one of the best growth stories in the sector. 

Vulcan Materials: An Industrial Foundation for 2026 

Rounding out our list of the best stocks for 2026, Vulcan Materials (NYSE: VMC) represents a core play on America’s infrastructure revival. As the largest U.S. aggregates and materials producer, it’s positioned to benefit directly from multi-year funding under the Infrastructure Investment and Jobs Act (IIJA) and continued state-level construction projects. 

VMC stock was up about 11.5% in 2025 and has been range-bound for much of the second half of the year. Nevertheless, strong pricing power, nationwide scale, and efficient operations make Vulcan a reliable cyclical performer. Its exposure to public works spending provides stability even if private construction softens.  

A potential trade: accumulate shares near $250, with upside toward $300 by mid-2026 as federal infrastructure dollars translate into record backlog growth. Investors aiming for diversified exposure could complement a Vulcan position with sector ETFs like PAVE or XLI. 

Building Long-Term Wealth With the Best Stocks for 2026 

The “best stocks for 2026” share one common trait — they’re not simply trading ideas but foundational holdings for a new growth cycle. Microsoft captures AI-driven productivity, Eli Lilly dominates in life-changing healthcare innovation, and Vulcan Materials anchors infrastructure expansion. Together, they represent a balanced portfolio blueprint built on structural demand and consistent execution. 

For investors setting 2026 resolutions, the opportunity lies in aligning with transformative, long-duration themes. By focusing on leaders with durable cash flows and visible earnings power, this year’s “best stocks for 2026” could help lay the groundwork for sustained wealth-building — long after the New Year’s champagne fades. 

But what should you look for? Let’s take as a given that investors should look for stocks with a dividend yield of around 3%. The most recent, if not necessarily reliable, inflation data we have puts inflation around 2.7%. It’s too early to tell if inflation will increase as monetary power loosens and stimulus is added to the economy. Nevertheless, a dividend of at least 3% will be needed to keep your investments ahead of inflation. 

These stocks provide investors with the benefit of reliable quarterly distributions that you can accept as cash in your bank account or that you can reinvest to increase your position in the stock.  

However, you should expect more from dividend stocks than reliable income. The stocks on this list also have a history of delivering a solid total return, which includes stock price appreciation to go along with a growing dividend. That’s how you maximize the benefits of compounding.  

Dividend Stocks to Buy: AbbVie

AbbVie Inc. (NYSE: ABBV) is hardly considered a comeback story. ABBV stock is up nearly 30% in 2025, and analysts are raising their price targets for the next 12 months. Outside of a company like Eli Lilly & Co. (NYSE: LLY), which is in a dominant position in the GLP-1 market, it’s been a rough year for pharmaceutical stocks. 

The key for AbbVie is that the company has successfully replaced the revenue it’s losing as its blockbuster Humira drug reached the patent cliff. But AbbVie’s patent-protected Skyrizi and Rinvoq are picking up the slack, and the company has a deep pipeline and a robust balance sheet that gives the company the firepower to get them across the finish line. 

AbbVie is also a dividend king, meaning it’s increased its dividend for at least 50 consecutive years. The yield as of this writing is 2.84% and is well covered by the company’s cash flow.  

Dividend Stocks to Buy: Bristol-Myers Squibb 

Bristol-Myers Squibb Co. (NYSE: BMY) has had a challenging few years as investors have cooled on large pharmaceutical names facing patent expirations. But value-minded dividend investors may find an opportunity as the stock appears deeply discounted relative to its historical valuation. The company trades at a forward P/E under 10 and offers a dividend yield in the 4.9% range—well above the market average. 

The fundamentals remain solid. Bristol-Myers is focusing on expanding newer drugs like Eliquis, Opdivo, and Reblozyl while investing in its pipeline of oncology and immunology therapies. Near-term results may stay lumpy, but with a steady cash flow profile and consistent earnings support, the dividend looks safe.

For contrarian investors, BMY provides a classic example of a high-yield stock with stabilization and upside potential if sentiment improves in 2026. 

Dividend Stocks to Buy: Pepsi 

PepsiCo Inc. (NASDAQ: PEP) offers a blend of income reliability and defensive growth that fits well in a 2026 portfolio rotation. While consumer staples stocks have lagged during the speculative surge into AI and tech, that underperformance has set the stage for better entry points. PepsiCo’s diversified product portfolio, from beverages to snacks, gives it pricing power and resilience even in a slower economy. 

The company has increased its dividend for more than 50 years, placing it among the Dividend Kings. Its yield of roughly 3% is comfortably above inflation, and its payout ratio of around 70% indicates room for further growth. As input cost pressures ease and global demand normalizes, PepsiCo looks positioned for mid-single-digit earnings growth alongside continued capital returns. 

Dividend Stocks to Buy: Enbridge 

Next on my list is Enbridge Inc. (NYSE: ENB), which is an energy infrastructure company. For starters, Enbridge has a high-yield dividend of 5.66% as of December 26. An above average yield can be a value trap, but that doesn’t appear to be the case with Enbridge.  

The catalyst is likely to be the company’s positioning with heavy crude oil. This is the type of crude oil needed for applications like diesel fuel. Unlike light crude oil, heavy crude inventories are low. That means countries with heavy oil resources, such as Canada, will benefit.  

Enbridge is the largest transporter of Western Canadian select. And the company has long-term contracts, a stable tolling model, and expansion opportunities that give investors exposure without the upstream risk.  

Dividend Stocks to Buy: Texas Instruments 

Texas Instruments Inc. (NASDAQ: TXN) stands out in the semiconductor space as one of the most dependable dividend payers. While many chipmakers lean heavily on cyclical end markets, TI’s strategy focuses on analog and embedded chips used in long-duration industrial and automotive applications—segments that provide stable, recurring demand. 

The company has raised its dividend for 20 consecutive years, and at a current yield near 3.3%, TXN offers an appealing blend of income and long-term growth. With its disciplined capital allocation, massive free cash flow generation, and conservative balance sheet, Texas Instruments embodies the kind of steady compounder that dividend investors can hold through multiple market cycles. 

The Bottom Line on High-Powered Dividend Stocks for 2026 

As the market transitions from speculative tech toward more income-focused investing, dividend stocks are regaining their appeal. The five companies highlighted here: AbbVie, Bristol-Myers Squibb, PepsiCo, Enbridge, and Texas Instruments, combine reliable dividend growth with the potential for solid total returns. 

They operate in diverse sectors, ranging from healthcare and consumer staples to energy and semiconductors, providing investors with balance and resilience across different market conditions. In 2026, when interest rates may finally stabilize and inflation holds near current levels, long-term dividend payers like these could quietly outperform, rewarding patient investors with steady income and compounding gains over time. 

And the good news for investors is that if this is a growth story, it’s still in its early stages. Goldman Sachs forecasts that the global anti-obesity medication market is likely to reach $95 billion by 2030 and may reach $120 billion by 2035.

With that in mind, investors should keep an eye on a trio of obesity stocks: Eli Lilly & Co. (NYSE: LLY), Viking Therapeutics (NASDAQ: VKTX), and Structure Therapeutics (NASDAQ: GPCR).

Obesity Stocks to Buy: Eli Lilly & Co.

Eli Lilly & Co. had the distinction of joining the exclusive club of stocks with a $1 trillion market cap. As of this writing, the stock has fallen back from that perch, but based on its commanding leadership in the GLP-1 market, it will likely reclaim that distincition soon.

LLY stock is up 33.8% in 2025. And recent price targets suggest there’s more growth to come.

Analysts at Bank of America reiterated a buy rating on Eli Lilly with a price target of $1,286 from $950. The firm states that Eli Lilly remains in first place in the obesity and diabetes market with its current GLP-1 franchise, Zepbound/Mounjaro. The firm also believes Eli Lilly will launch its new oral medication for obesity in early 2026, rather than later in the year.

Obesity Stocks to Buy: Viking Therapeutics

Viking Therapeutics stock is down 12% in 2025. However, it’s climbed over 31% in the three months ending December 3. With the stock trading at $35.41, VKTX could explode even higher.

In fact, analysts have a consensus price target of $87.14 on VKTX stock, a gain of nearly 149% from its current level. Hitting that target will be contingent on the company seeing further positive results with its obesity trials.  

Recently, VKTX initiated its VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The company is also making progress with both oral and subcutaneous formulations for the potential treatment.

Also, according to Brian Lian, Ph.D., CEO of Viking.  “Along with the successful initiation of the Phase 3 program we continue to make progress on VK2735’s broader development.  This includes our plans to initiate an additional clinical study to evaluate a monthly maintenance regimen, which is expected to begin later this year.  We also continue to build on the encouraging early data reported for the oral tablet formulation of VK2735 and expect to report the results of the Phase 2 VENTURE-Oral Dosing study in the second half of this year.” 

Adding to investor enthusiasm are rumors that a company like Pfizer could potentially buy a company like this one. Especially after PFE CEO Albert Bourla said the company could seek deals to add obesity therapies to strengthen its pipeline.

Obesity Stocks to Buy: Structure Therapeutics 

Structure Therapeutics may appeal to investors who have an appetite for the volatility that comes with small-cap stocks. The distinction between Structure Therapeutics and the other obesity stocks on this list is that it’s a clinical-stage company. That means it doesn’t have a product that’s commercially available.

It also means that the company is not profitable and has very little revenue. However, buying clinical-stage biopharmaceutical stocks can be like buying a lottery ticket. If it hits, they can be very profitable.

The company recently reported positive topline data from its Phase 2a obesity study of GSBR-1290, which “demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks,” according to a company press release.

GPCR is also on track to initiate a 36-week Phase 2b study of GSBR-1290 in the fourth quarter of the year. Should it continue to show solid progress, shares of GPCR could easily push aggressively higher.